3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
87
Leukemia
73
Leukemia, Myeloid, Acute
70
Precursor Cell Lymphoblastic Leukemia-Lymphoma
56
Lymphoma
42
Myeloproliferative Disorders
38
Lymphoma, Non-Hodgkin
38
Hodgkin Disease
37
Multiple Myeloma
34
Leukemia, Myeloid, Chronic-Phase
34
Leukemia, Lymphocytic, Chronic, B-Cell
34
Leukemia, Myeloid, Accelerated Phase
32
Burkitt Lymphoma
32
Leukemia, Myelomonocytic, Chronic
29
Lymphoma, Follicular
28
Lymphoma, Mantle-Cell
27
Lymphoma, Large B-Cell, Diffuse
27
Lymphoma, Large-Cell, Immunoblastic
26
Blast Crisis
26
Lymphoma, B-Cell, Marginal Zone
25
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Neoplasms, Plasma Cell
24
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
24
Congenital Abnormalities
24
Myelodysplastic-Myeloproliferative Diseases
23
Anemia, Refractory, with Excess of Blasts
23
Dendritic Cell Sarcoma, Interdigitating
22
Primary Myelofibrosis
19
Recurrence
17
Leukemia, Biphenotypic, Acute
17
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Filgrastim
×
Myeloid
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled